Treatment of Wegener's Granulomatosis With Cyclophosphamide

National Institute of Allergy and Infectious Diseases (NIAID)200 enrolled

Overview

The purpose of this protocol is to continue to treat patients with Wegener's granulomatosis who have already entered the study, and to treat new patients. The investigators will attempt to correlate the clinical response with specific immunosuppressive effects of drug administration. The investigators are accumulating data on the optimal duration and side effects of therapy.

The purpose of the protocol is to continue to treat patients with Wegener's granulomatosis who have already entered the study, and to treat new patients. The investigators will attempt to correlate the clinical response with specific immunosuppressive effects of drug administration. The investigators are accumulating data on the optimal duration and side effects of therapy. Age Range: greater than 1 year

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Enrollment

200

Conditions

Vasculitis Wegener's Granulomatosis

Interventions

cyclophosphamideDRUG

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Patients greater than 1 year of age with the clinical and pathological diagnosis of WG whose illness presents a risk of permanent disability or death. Examples of processes that impart risk of permanent disability or death include: peripheral and central nervous system disease, cardiac involvement, glomerulonephritis, and vascular comprise of gastrointestinal organs. No women who are pregnant or intend to become pregnant. No patients who have known malignancies. Patients must be HIV negative.

Locations (1)

National Institute of Allergy and Infectious Diseases (NIAID)

Bethesda, Maryland, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.